NF-κB Signaling and EBC-46: How Tigilanol Tiglate Activates Inflammatory Pathways in Tumour Cells
Published mechanistic work links EBC-46 to NF-κB activation downstream of PKC. This article summarises how that pathway shapes the local inflammatory cascade after intratumoural injection.
The published mechanistic literature on tigilanol tiglate (EBC-46) describes a cascade of cellular events that begins with PKC activation and ends with rapid tumour cell death and vascular collapse. One of the less-discussed steps in that cascade is the activation of the NF-κB transcription factor — a regulator of inflammatory and stress-response gene expression that helps explain why intratumoural injection produces the dramatic local inflammation that characterises EBC-46 treatment in published trials.
NF-κB and the inflammatory cascade
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that, when activated, translocate to the nucleus and switch on hundreds of genes involved in inflammation, immune cell recruitment, and cell survival. In healthy tissue, NF-κB activation is a normal response to injury or pathogen exposure. In the tumour microenvironment, the same pathway can be hijacked for chronic, low-grade inflammation that supports tumour growth — but it can also be acutely re-activated in ways that drive innate immune attack on tumour cells.
How EBC-46 plugs into the pathway
Published mechanistic work shows tigilanol tiglate activates protein kinase C (PKC) by binding to the C1 domain — the same site that normally recognises diacylglycerol (DAG). Downstream of PKC activation, multiple kinase cascades are triggered, one of which is the IKK complex that phosphorylates IκB and releases NF-κB to enter the nucleus. The result, in injected tumour tissue, is rapid upregulation of inflammatory cytokines, including TNF-α and IL-6, and chemokines that recruit neutrophils into the tumour bed.
Why this matters for the observed treatment effect
The QBiotics Phase I/II data describe a stereotyped local inflammatory response after intratumoural injection: a window of swelling and erythema, followed within hours by tumour necrosis, then over days a programmed wound-healing response. The NF-κB-driven cytokine surge is a plausible early mediator of that sequence. Crucially, this is acute, time-limited inflammation — not the chronic NF-κB activation associated with tumour-promoting inflammation in untreated cancers. The published mechanistic paper by Boyle et al. (2014) established the PKC-binding step; subsequent work has filled in the downstream signalling, including the role of NF-κB-dependent cytokine release in the immediate hours after dosing.
Distinguishing pharmaceutical and supplement contexts
All of the NF-κB and PKC mechanistic data come from studies of pharmaceutical-grade tigilanol tiglate administered intratumourally — the formulation marketed for veterinary use as Stelfonta and trialled in humans by QBiotics. Oral blushwood berry extract supplements are a different proposition: they contain whole-seed extract at declared ratios (commonly 10:1) and are not pharmaceutical isolates. There is no published clinical evidence demonstrating systemic NF-κB modulation from oral supplementation, and dietary supplement brands such as Blushwood Health make no therapeutic claims to that effect, in line with FDA dietary supplement requirements.
Open questions in the mechanism literature
Several aspects of the NF-κB story remain incompletely characterised. The first is selectivity — why injected tigilanol tiglate produces a strong inflammatory response confined to the tumour bed rather than diffusing systemically. The leading hypothesis is rapid local PKC saturation combined with poor systemic bioavailability of the injected dose. A second open question is the duration of NF-κB activation: is it a single pulse or does it sustain over the wound-healing phase? And third, how does NF-κB activation interact with the macrophage polarisation shifts described elsewhere in the tumour microenvironment? These are active areas of research and matter for any future translational programme.
Practical implications
For readers tracking the mechanism literature, NF-κB activation should be understood as one node in a broader signalling network rather than a stand-alone driver. The therapeutic story for tigilanol tiglate sits in the integrated cascade: PKC binding, calcium and DAG mimicry, NF-κB-mediated cytokine release, neutrophil recruitment, vascular collapse, tumour cell death, and orchestrated wound healing. Each step has been characterised in increasing detail by QBiotics and academic collaborators since the original 2014 publication.
Related articles
calcium-dependent PKC activation by EBC-46macrophage polarization in the tumour microenvironment
Citations
2. QBiotics Group — Tigilanol Tiglate Programme Overview.
3. Hayden MS, Ghosh S — NF-κB in Immunobiology, Cell Research (2011).
Statements about dietary supplements have not been evaluated by the Food and Drug Administration. Any blushwood-berry supplement is not intended to diagnose, treat, cure, or prevent any disease.
